Cargando…
Markers of Aggressiveness in Craniopharyngiomas
Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090695/ http://dx.doi.org/10.1210/jendso/bvab048.1317 |
_version_ | 1783687345329930240 |
---|---|
author | Del Can-Sanchez, Diego Jesús Sanchez, Diego Jesus Del Can Martínez-Ortega, Antonio Jesús Flores-Martínez, Alvaro Venegas-Moreno, Eva Dios-Fuentes, María Elena Madrazo-Atutxa, Ainara Valdepeñas, Eugenio Cárdenas-Ruiz Kaen, Ariel Matías Márquez-Rivas, Francisco Javier Roldán-Lora, Anastasia Florinda Fajardo-Picó, Elena Cano-González, David Soto-Moreno, Alfonso |
author_facet | Del Can-Sanchez, Diego Jesús Sanchez, Diego Jesus Del Can Martínez-Ortega, Antonio Jesús Flores-Martínez, Alvaro Venegas-Moreno, Eva Dios-Fuentes, María Elena Madrazo-Atutxa, Ainara Valdepeñas, Eugenio Cárdenas-Ruiz Kaen, Ariel Matías Márquez-Rivas, Francisco Javier Roldán-Lora, Anastasia Florinda Fajardo-Picó, Elena Cano-González, David Soto-Moreno, Alfonso |
author_sort | Del Can-Sanchez, Diego Jesús |
collection | PubMed |
description | Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to recurrence in CP. Material and Methods: Descriptive retrospective observational study of patients with confirmed histology of CP and tissue sample available admitted to Virgen Del Rocio University Hospital (Seville, Spain) from January 1967 to October 2020 were included. Estrogen and progesterone receptor expression was analyzed by Immunohistochemistry. Ki-67 levels were also analyzed. Two CP groups were considereded according to Ki67 levels: Group A (Ki67<10%) and group B (Ki67>10%). As all variables followed a non-parametric distribution, U Mann Whitney, Chi-Square, and Z-test with Benjamini-Hochberg correction were used when needed. Results: Our study population includes 80 patients (46 male and 34 female), with a median age at diagnosis of 34 years [10-50.00]. Twenty-six patients were under 18 years old (children) with a median age of 7 years [4.5-10.00], and 54 were adults (aged 18 and above) with a median age of 45 years [33-58.50]. Our data shows higher recurrence rates when Ki67 levels staining were higher than 10%: 8/14 (57.2%) in comparison with Ki67<10% (6/14, 42.9%, p=0.018). In children we found 6 samples with Ki67<10% and 6 samples with Ki67 >10%; recurrences were observed in 2/6 (33,3%) in the first group and in 6/6 (100%) in the second, respectively (p= 0,199). In adults, we found 9 and 3 patients for high and low Ki67 levels, respectively. Recurrences were observed in 4/9 (44,4%) in the group A and in 2/3 (66,7%) in the group B, respectively (p= 0,28). There were no differences between age groups. In patients with positive ER, we observed an increased rate of recurrence: 12/23 (52.17%) versus 2/13 (15,38%) in patients with negative ER stain but it was no significant. (p=0,21). No association between PR and recurrence was observed. Conclusions: In our series, patients with CP with high Ki67 levels are more likely to recur. No clear association between ER, PR expression and recurrence was observed. These findings support the use of Ki67 as a marker of recurrence in CP. Sources of Research Support: Spanish Ministry of Health, ISCIII co-funded with Fondos FEDER (PI16/00175) and Novartis Oncology Spain. |
format | Online Article Text |
id | pubmed-8090695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80906952021-05-12 Markers of Aggressiveness in Craniopharyngiomas Del Can-Sanchez, Diego Jesús Sanchez, Diego Jesus Del Can Martínez-Ortega, Antonio Jesús Flores-Martínez, Alvaro Venegas-Moreno, Eva Dios-Fuentes, María Elena Madrazo-Atutxa, Ainara Valdepeñas, Eugenio Cárdenas-Ruiz Kaen, Ariel Matías Márquez-Rivas, Francisco Javier Roldán-Lora, Anastasia Florinda Fajardo-Picó, Elena Cano-González, David Soto-Moreno, Alfonso J Endocr Soc Neuroendocrinology and Pituitary Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to recurrence in CP. Material and Methods: Descriptive retrospective observational study of patients with confirmed histology of CP and tissue sample available admitted to Virgen Del Rocio University Hospital (Seville, Spain) from January 1967 to October 2020 were included. Estrogen and progesterone receptor expression was analyzed by Immunohistochemistry. Ki-67 levels were also analyzed. Two CP groups were considereded according to Ki67 levels: Group A (Ki67<10%) and group B (Ki67>10%). As all variables followed a non-parametric distribution, U Mann Whitney, Chi-Square, and Z-test with Benjamini-Hochberg correction were used when needed. Results: Our study population includes 80 patients (46 male and 34 female), with a median age at diagnosis of 34 years [10-50.00]. Twenty-six patients were under 18 years old (children) with a median age of 7 years [4.5-10.00], and 54 were adults (aged 18 and above) with a median age of 45 years [33-58.50]. Our data shows higher recurrence rates when Ki67 levels staining were higher than 10%: 8/14 (57.2%) in comparison with Ki67<10% (6/14, 42.9%, p=0.018). In children we found 6 samples with Ki67<10% and 6 samples with Ki67 >10%; recurrences were observed in 2/6 (33,3%) in the first group and in 6/6 (100%) in the second, respectively (p= 0,199). In adults, we found 9 and 3 patients for high and low Ki67 levels, respectively. Recurrences were observed in 4/9 (44,4%) in the group A and in 2/3 (66,7%) in the group B, respectively (p= 0,28). There were no differences between age groups. In patients with positive ER, we observed an increased rate of recurrence: 12/23 (52.17%) versus 2/13 (15,38%) in patients with negative ER stain but it was no significant. (p=0,21). No association between PR and recurrence was observed. Conclusions: In our series, patients with CP with high Ki67 levels are more likely to recur. No clear association between ER, PR expression and recurrence was observed. These findings support the use of Ki67 as a marker of recurrence in CP. Sources of Research Support: Spanish Ministry of Health, ISCIII co-funded with Fondos FEDER (PI16/00175) and Novartis Oncology Spain. Oxford University Press 2021-05-03 /pmc/articles/PMC8090695/ http://dx.doi.org/10.1210/jendso/bvab048.1317 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuroendocrinology and Pituitary Del Can-Sanchez, Diego Jesús Sanchez, Diego Jesus Del Can Martínez-Ortega, Antonio Jesús Flores-Martínez, Alvaro Venegas-Moreno, Eva Dios-Fuentes, María Elena Madrazo-Atutxa, Ainara Valdepeñas, Eugenio Cárdenas-Ruiz Kaen, Ariel Matías Márquez-Rivas, Francisco Javier Roldán-Lora, Anastasia Florinda Fajardo-Picó, Elena Cano-González, David Soto-Moreno, Alfonso Markers of Aggressiveness in Craniopharyngiomas |
title | Markers of Aggressiveness in Craniopharyngiomas |
title_full | Markers of Aggressiveness in Craniopharyngiomas |
title_fullStr | Markers of Aggressiveness in Craniopharyngiomas |
title_full_unstemmed | Markers of Aggressiveness in Craniopharyngiomas |
title_short | Markers of Aggressiveness in Craniopharyngiomas |
title_sort | markers of aggressiveness in craniopharyngiomas |
topic | Neuroendocrinology and Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090695/ http://dx.doi.org/10.1210/jendso/bvab048.1317 |
work_keys_str_mv | AT delcansanchezdiegojesus markersofaggressivenessincraniopharyngiomas AT sanchezdiegojesusdelcan markersofaggressivenessincraniopharyngiomas AT martinezortegaantoniojesus markersofaggressivenessincraniopharyngiomas AT floresmartinezalvaro markersofaggressivenessincraniopharyngiomas AT venegasmorenoeva markersofaggressivenessincraniopharyngiomas AT diosfuentesmariaelena markersofaggressivenessincraniopharyngiomas AT madrazoatutxaainara markersofaggressivenessincraniopharyngiomas AT valdepenaseugeniocardenasruiz markersofaggressivenessincraniopharyngiomas AT kaenarielmatias markersofaggressivenessincraniopharyngiomas AT marquezrivasfranciscojavier markersofaggressivenessincraniopharyngiomas AT roldanloraanastasiaflorinda markersofaggressivenessincraniopharyngiomas AT fajardopicoelena markersofaggressivenessincraniopharyngiomas AT canogonzalezdavid markersofaggressivenessincraniopharyngiomas AT sotomorenoalfonso markersofaggressivenessincraniopharyngiomas |